Commissioner Hamburg: Moving FDA Beyond A Regulatory Agency
This article was originally published in The Tan Sheet
Of the leading candidates for FDA commissioner in the Obama administration, Margaret Hamburg seemed among those with the least relevant experience -- an illustrious career to be sure, but one that lacked a decision-making role involving medical products
You may also be interested in...
Winckler heads FDLI: The Food and Drug Law Institute names Susan Winckler, a former FDA chief of staff, as its president and CEO. Effective Nov. 6, Winckler replaced James Kelly, who announced his departure at the end of the summer. Winckler, a pharmacist and attorney who also has been VP of policy and communications and staff counsel for the American Pharmacists Association, joined FDA as director for policy communications in September 2006 under former Commissioner Andrew von Eschenbach, coordinating staff activities in the Office of the Commissioner and serving as the principal liaison to the Department of Health and Human Services. In January 2007 she took on a stronger formal role in FDA's newly created Office of the Chief of Staff, where she served as the main point of contact between the agency's centers and offices and the commissioner. Winckler left FDA in June after Commissioner Margaret Hamburg began appointing her own executive staff (1"The Tan Sheet" July 27, 2009)
FDA tweets about new drug approvals, safety alerts, compliance actions and consumer information to improve communication to the public and regulated industries, the agency announces Sept. 14. FDA began tweeting @FDA_Drug_Info more than a month ago and has more than 1,500 followers. The Twitter account is one way FDA Commissioner Margaret Hamburg is increasing transparency (1"The Tan Sheet" July 27, 2009)
Advertising health claims and promotion of medical products are squarely in mind for FDA Commissioner Peggy Hamburg